CORT Corcept Therapeutics: FDA approves Korlym for patients with endogenous Cushing’s syndrome- stock is halted (3.03 +0.15) -Update- Click here for FDA story. 16:20 CORT Corcept Therapeutics halted (3.03 +0.15) 16:17